ILMN Stock Keeps Climbing. Should You Climb On?

A gene sequencing leader is on a powerful run fueled by real business quality, forcing investors to decide if the engine has more power than the price tag already reflects.

Illumina (ILMN), a maker of gene sequencing technology, has handed investors a classic momentum problem. The stock has had a powerful run in the last year, placing it in the top 3% of U.S. stocks with a market cap above $1 billion on trend strength. It’s the kind of performance that creates both a fear of chasing and a fear of being left behind. The engine behind the move is real, but so is the price. The open question for any would-be buyer is whether this is a pause in a powerful trend, or if the market has already charged for all the good news.

The run is powered by a real clinical engine.

This is not a story stock. Illumina’s momentum is anchored in tangible business quality and demand. Its operating margin over the last twelve months is 19.9%, beating the S&P 500 median of 18.6%. The company’s operating cash flow margin is also superior, at 24% versus a market median of 22%. This recent margin expansion is a sharp improvement over its three-year average of 13.4%, though it remains to be seen whether Illumina can sustain profitability above the market median.

The primary driver is accelerating adoption in clinical markets, particularly in the U.S. and Canada. Management notes that demand for its flagship NovaSeq X sequencing system “remained high more than three years after launch,” with the company placing more than 95 new systems last quarter. This expanding installed base is expected to pull through more high-margin consumables for years, giving management the confidence to raise its full-year outlook. They now expect full-year rest-of-the-world organic revenue growth greater than 5%.

The market charges a premium and sees a slowdown ahead.

A ticket on this train is not cheap. Illumina trades at a price-to-earnings multiple of 39.9, a steep premium to the S&P 500 median of 23.2. The stock sits roughly 4% below its two-year high of $227.69, reached just last month. This valuation is particularly rich when you note that its revenue over the last twelve months grew 4.9%, versus an S&P 500 median revenue growth of 8.4%.

The honest catch is that the growth story has two distinct speeds. While the clinical business is thriving, management continues to expect “mid-to-high single-digit declines for research and applied consumables in 2026.” This weakness in the academic and research market, a traditional source of innovation, is a persistent drag. For investors interested in the broader life sciences tools space, it’s worth watching how peers are navigating their own earnings.

Furthermore, the torrid pace of the last quarter is not expected to continue. After posting 8.1% organic growth outside of Greater China, management’s guidance for the third quarter implies a significant deceleration.

The next quarter’s growth rate is the test.

For Illumina, the debate comes down to a single, clear test. Management has guided investors to expect approximately 4.5% rest-of-world organic revenue growth—a metric Illumina defines as excluding Greater China—for the third quarter. Hitting or exceeding that number would signal that the clinical engine is strong enough to overcome the research market’s drag and sustain momentum. A miss, or a downward revision to the full-year outlook, would give weight to the argument that the stock’s premium valuation has outrun the business’s near-term reality. That figure is the one to watch.

For more runs powered by rising forecasts rather than pure sentiment, our Guidance Momentum screen surfaces exactly those setups, daily.

Those drawn to the run but not the single-name risk have another route: our ETF Scorecard shows how the health care funds stack up. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.

The Engine Matters More Than The Speed

What separates a run worth joining from a run worth watching is the business underneath, and checking that engine name by name, quarter after quarter, is a full-time job.

That is the job the Trefis High Quality (HQ) Portfolio does systematically: roughly 30 businesses screened for margins, cash generation, and balance-sheet strength, sized and re-balanced with discipline. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Keep an eye on the fast movers; anchor your money to the engines.